Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma.
Heather A JaceneJohn CrandallYvette L KasamonRichard F AmbinderSteven PiantadosiDonna SerenaWayne KasecampRichard L WahlPublished in: Molecular imaging and biology (2018)
Tositumomab and [131I]tositumomab was well-tolerated in patients with relapsed/refractory HL. Complete responses in LPHL support a therapeutic effect in this subtype. Early metabolic response assessments by [18F]DG-PET in HL after radioimmunotherapy appear to be more predictive than purely anatomic assessments.